Compositions and methods for making and using anti-myostatin antibodies

1. A method of making a pharmaceutical composition comprising a myostatin-selective inhibitor, the method comprising:

(i) screening for an antibody or an antigen-binding fragment thereof that selectively binds to myostatin and/or a protein complex comprising myostatin and is capable of decreasing expression of pyruvate dehydrogenase kinase 4 (PDK4) and increasing expression of pyruvate dehydrogenase phosphatase 1 (PDP1) in a human subject after administration to the subject;

(ii) culturing host cells comprising one or more polynucleotides encoding the antibody or antigen-binding fragment under conditions that allow for expression of the antibody or antigen-binding fragment;

(iii) purifying the antibody or antigen-binding fragment from the culture; and,

(iv) formulating the antibody or antigen-binding fragment into a pharmaceutical composition suitable for administration to the subject, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

2. The method of claim 1 , wherein the host cells are CHO cells, 293 cells, or NSO cells.

3. The method of claim 1 , wherein the pharmaceutical composition is formulated for subcutaneous administration to a subject.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment is screened for the ability to bind to Activin A, wherein the antibody or antigen-binding fragment does not bind to Activin A.

5. The method of claim 1 , wherein the pharmaceutical composition further comprises an insulin secretion-promoting agent.

6. The method of claim 1 , wherein the subject has or is at risk of developing a metabolic disease, wherein optionally the metabolic disease is obesity.

7. The method of claim 6 , wherein the obesity is obesity associated with type II diabetes.